• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study
This study details the design of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study – a postauthorization observational study, which is part of the postapproval plan for edoxaban agreed with the European Medicines Agency. Methods The ETNA-AF-Europe study (Clinicaltrials.gov: NCT02944019) is a multicenter, prospective, observational study that enrolled 13 980 patients with atrial fibrillation treated with edoxaban from 852 sites across 10 European countries (Austria, Belgium, Germany, Ireland, Italy, the Netherlands, Portugal, Spain, Switzerland,...
Source: Journal of Cardiovascular Medicine - January 3, 2019 Category: Cardiology Tags: Research articles: Trial design Source Type: research

Po-652-06 a novel measure to identify inequity in the treatment of atrial fibrillation: decreased access to cardioversion/ablation in counties with low health rankings
Adequate treatment of atrial fibrillation (AF) is critical for managing patient stroke risk and quality of life. Cardioversion and ablation (CV/A) procedures are commonly performed to treat AF, yet differences in access to these treatments have not been explored from a population health perspective.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Ashley E. Burch, Jan Wong, William Irish Source Type: research